Organisation paid for research Program year 2025 Source: CMS Open Payments

Shelby Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,615,286

550 payments

Through program year 2025, Shelby Research LLC is reported as receiving $2,615,286 in research payments, across 550 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $168,774 35
2024 Research $342,821 55
2023 Research $345,187 70
2022 Research $478,745 111
2021 Research $500,050 92
2020 Research $306,992 96
2019 Research $472,719 91

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $505,843 105 payments
  2. Janssen Research & Development, LLC $490,469 110 payments
  3. Gilead Sciences, Inc. $340,327 107 payments
  4. Pfizer Inc. $243,898 59 payments
  5. Regeneron Pharmaceuticals, Inc. $219,525 31 payments
  6. Horizon Therapeutics plc $194,169 2 payments
  7. E.R. Squibb & Sons, L.L.C. $155,657 6 payments
  8. Ucb SA $146,168 33 payments
  9. AstraZeneca UK Limited $123,768 2 payments
  10. Sun Pharmaceutical Industries Inc. $82,331 35 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus $426,046 78 payments
  2. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $218,495 30 payments
  3. A Phase 2B Doubleblind Randomized Placebocontrolled Multicenter Doseranging Study to Evaluate the Efficacy and Safety Profile of Pf06700841 in Participants With Active Systemic Lupus Erythematosus Sle $126,839 32 payments
  4. A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus $123,768 2 payments
  5. A Ph2 Doubleblind Randomized Placebocontrolled Multicenter Doseranging Study to Evaluate the Efficacy and Safety Profile of Pf06700841 in Subjects With Systemic Lupus Erythematosus $117,059 27 payments
  6. A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Vib4920 in Subjects With Sjogren's Syndrome (SS) $109,886 1 payment
  7. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $109,051 22 payments
  8. A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $103,060 12 payments
  9. Phase III SLE - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) $89,991 1 payment
  10. Vib4920.P2.S2 $84,283 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $60,136 21 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record